<SEC-DOCUMENT>0001213900-25-005155.txt : 20250121
<SEC-HEADER>0001213900-25-005155.hdr.sgml : 20250121
<ACCEPTANCE-DATETIME>20250121192118
ACCESSION NUMBER:		0001213900-25-005155
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20250116
FILED AS OF DATE:		20250121
DATE AS OF CHANGE:		20250121

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			HILZ MARK T
		CENTRAL INDEX KEY:			0001016157
		STANDARD INDUSTRIAL CLASSIFICATION:	WHOLESALE-COMPUTER & PERIPHERAL EQUIPMENT & SOFTWARE [5045]
		ORGANIZATION NAME:           	07 Trade & Services
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41422
		FILM NUMBER:		25543610

	MAIL ADDRESS:	
		STREET 1:		3301 DAKOTA DRIVE
		CITY:			NORTHLAKE
		STATE:			TX
		ZIP:			76226

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HeartSciences Inc.
		CENTRAL INDEX KEY:			0001468492
		STANDARD INDUSTRIAL CLASSIFICATION:	ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				261344466
		STATE OF INCORPORATION:			TX
		FISCAL YEAR END:			0430

	BUSINESS ADDRESS:	
		STREET 1:		550 RESERVE ST, SUITE 360
		CITY:			SOUTHLAKE
		STATE:			TX
		ZIP:			76092
		BUSINESS PHONE:		682-237-7781

	MAIL ADDRESS:	
		STREET 1:		550 RESERVE ST, SUITE 360
		CITY:			SOUTHLAKE
		STATE:			TX
		ZIP:			76092

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Heart Test Laboratories, Inc.
		DATE OF NAME CHANGE:	20090716
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>ownership.xml
<DESCRIPTION>OWNERSHIP DOCUMENT
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0508</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2025-01-16</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0001468492</issuerCik>
        <issuerName>HeartSciences Inc.</issuerName>
        <issuerTradingSymbol>HSCS</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001016157</rptOwnerCik>
            <rptOwnerName>HILZ MARK T</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O HEARTSCIENCES INC.,</rptOwnerStreet1>
            <rptOwnerStreet2>550 RESERVE STREET, SUITE 360</rptOwnerStreet2>
            <rptOwnerCity>SOUTHLAKE</rptOwnerCity>
            <rptOwnerState>TX</rptOwnerState>
            <rptOwnerZipCode>76092</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>1</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle>See Remarks</officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>0</aff10b5One>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Employee Stock Option (Right to Buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>3.33</value>
                <footnoteId id="F1"/>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2025-01-16</value>
            </transactionDate>
            <deemedExecutionDate></deemedExecutionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionTimeliness></transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>45000</value>
                </transactionShares>
                <transactionPricePerShare>
                    <footnoteId id="F1"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F2"/>
            </exerciseDate>
            <expirationDate>
                <value>2035-01-16</value>
                <footnoteId id="F3"/>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>45000</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>45000</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">These options were granted to the Reporting Person effective as of January 16, 2025 (the &quot;Effective Date&quot;), pursuant to the approval of the compensation committee of the Issuer's board of directors.</footnote>
        <footnote id="F2">One-third of the options shall vest on the 12-month anniversary of the Effective Date, with an additional 8.333% of the options vesting on each of April 16, 2026 (the &quot;Subsequent Vesting Date&quot;) and thereafter on each successive three-month anniversary of the Subsequent Vesting Date for the next seven fiscal quarters, subject to the Reporting Person's continued employment with the Issuer through each applicable vesting date and subject to the terms of the Issuer's 2023 Equity Incentive Plan (the &quot;2023 Plan&quot;). These options shall become fully-vested and may be exercised at any time at the Reporting Person's election upon the Issuer receiving regulatory clearance for its MyoVista wavECG device or AI-ECG algorithm (subject to certain requirements) (or similar such product owned by the Issuer) from the U.S. Food and Drug Administration. As of the date of this filing, such regulatory clearance has not been received.</footnote>
        <footnote id="F3">These options expire ten years from the Effective Date, unless terminated sooner in accordance with the Issuer's 2023 Plan or the underlying options grant agreement.</footnote>
    </footnotes>

    <remarks>Chief Operating Officer and Secretary</remarks>

    <ownerSignature>
        <signatureName>/s/ Andrew Simpson, Attorney-in-fact</signatureName>
        <signatureDate>2025-01-21</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
